The Guardian view on cancer survival rates: there is good news about healthcare amid the gloom | Editorial

"Stand back from the day to day, and the extraordinary leaps forward enabled by vaccinations and other advances in treatment and public health come into focus. This longer view is not a cause for complacency or inaction. England's latest cancer plan, launched last month, highlighted shocking lapses including lengthy waits for treatment and a failure to tackle inequalities in cancer mortality dating back 15 years."

"Over the past decade, deaths from kidney, liver and some other cancers have risen. And Brexit has had an adverse impact on the development of new treatments, with researchers facing a trickier environment for clinical trials. One report last year pointed to the increased difficulty of international collaboration, reduced access to grant funding and border controls hindering the ability of experts to move around."

"One in two people in the UK will get a cancer diagnosis at some point in their lives and cancer care is a high priority for voters. The overall number of people dying from the disease continues to rise as the population ages."

Cancer Research UK analysis shows a 29% reduction in cancer death rates over 40 years, representing significant medical progress through vaccinations and treatment advances. However, this long-term success masks current challenges. England's latest cancer plan reveals critical issues including lengthy treatment waits and persistent 15-year inequalities in cancer mortality. Most NHS trusts fail to meet diagnosis and treatment standards. Deaths from kidney, liver, and other cancers have risen over the past decade. Brexit has complicated clinical trials and international research collaboration, reducing funding access and expert mobility. With one in two UK residents facing cancer diagnosis and an aging population increasing overall deaths, cancer remains a voter priority. Recent policy initiatives acknowledge these challenges while recognizing the 11% death rate decline over the past decade.

Read at www.theguardian.com